Evidence map›Paper›PMID 34118963›Full record

ArticleRadiation oncology (London, England)2021

Impact of superparamagnetic iron oxide nanoparticles on in vitro and in vivo radiosensitisation of cancer cells.

Emily Russell, Victoria Dunne, Ben Russell, Hibaaq Mohamud, Mihaela Ghita, Stephen J McMahon, Karl T Butterworth, Giuseppe Schettino, Conor K McGarry, Kevin M Prise

Open access · goldAbstract read
In one paragraph

Article in Radiation oncology (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Review
  3. Biomimetic FeCurrent pharmaceutical biotechnology · 2026
    Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Functionalized Magnetic FeInternational journal of molecular sciences · 2024
    Article
  14. Article
  15. Article
  16. Review
  17. Nanoparticles in Medicine: Current Status in Cancer Treatment.International journal of molecular sciences · 2023
    Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Emily RussellPatrick G. Johnston Centre for Cancer Research, Queen's University, Belfast, UK. erussell11@qub.ac.uk.ORCID http://orcid.org/0000-0003-0397-5594
Victoria DunnePatrick G. Johnston Centre for Cancer Research, Queen's University, Belfast, UK.
Ben RussellNational Physical Laboratory, London, UK.
Hibaaq MohamudNational Physical Laboratory, London, UK.
Mihaela GhitaPatrick G. Johnston Centre for Cancer Research, Queen's University, Belfast, UK.
Stephen J McMahonPatrick G. Johnston Centre for Cancer Research, Queen's University, Belfast, UK.
Karl T ButterworthPatrick G. Johnston Centre for Cancer Research, Queen's University, Belfast, UK.
Giuseppe SchettinoNational Physical Laboratory, London, UK.
Conor K McGarryPatrick G. Johnston Centre for Cancer Research, Queen's University, Belfast, UK.
Kevin M PrisePatrick G. Johnston Centre for Cancer Research, Queen's University, Belfast, UK.
Queen's University Belfast · GBNational Physical Laboratory · GB

Funding

Medical Research Council MR/P01593X/1
6 · The paper itself

Abstract

purposeThe recent implementation of MR-Linacs has highlighted theranostic opportunities of contrast agents in both imaging and radiotherapy. There is a lack of data exploring the potential of superparamagnetic iron oxide nanoparticles (SPIONs) as radiosensitisers. Through preclinical 225 kVp exposures, this study aimed to characterise the uptake and radiobiological effects of SPIONs in tumour cell models in vitro and to provide proof-of-principle application in a xenograft tumour model.

methodsSPIONs were also characterised to determine their hydrodynamic radius using dynamic light scattering and uptake was measured using ICP-MS in 6 cancer cell lines; H460, MiaPaCa2, DU145, MCF7, U87 and HEPG2. The impact of SPIONs on radiobiological response was determined by measuring DNA damage using 53BP1 immunofluorescence and cell survival. Sensitisation Enhancement Ratios (SERs) were compared with the predicted Dose Enhancement Ratios (DEFs) based on physical absorption estimations. In vivo efficacy was demonstrated using a subcutaneous H460 xenograft tumour model in SCID mice by following intra-tumoural injection of SPIONs.

resultsThe hydrodynamic radius was found to be between 110 and 130 nm, with evidence of being monodisperse in nature. SPIONs significantly increased DNA damage in all cell lines with the exception of U87 cells at a dose of 1 Gy, 1 h post-irradiation. Levels of DNA damage correlated with the cell survival, in which all cell lines except U87 cells showed an increased sensitivity (P < 0.05) in the linear quadratic curve fit for 1 h exposure to 23.5 μg/ml SPIONs. There was also a 30.1% increase in the number of DNA damage foci found for HEPG2 cells at 2 Gy. No strong correlation was found between SPION uptake and DNA damage at any dose, yet the biological consequences of SPIONs on radiosensitisation were found to be much greater, with SERs up to 1.28 ± 0.03, compared with predicted physical dose enhancement levels of 1.0001. In vivo, intra-tumoural injection of SPIONs combined with radiation showed significant tumour growth delay compared to animals treated with radiation or SPIONs alone (P < 0.05).

conclusionsSPIONs showed radiosensitising effects in 5 out of 6 cancer cell lines. No correlation was found between the cell-specific uptake of SPIONs into the cells and DNA damage levels. The in vivo study found a significant decrease in the tumour growth rate.

Indexed as

Gamma RaysAnimalsApoptosisCell ProliferationHumansMagnetic Iron Oxide NanoparticlesMiceMice, SCIDNeoplasmsRadiation-Sensitizing AgentsTumor Cells, CulturedXenograft Model Antitumor AssaysRadiation-Sensitizing AgentsNanoparticlesRadiobiology

Identifiers

PMID34118963
PMCPMC8199842
OpenAlexW3169847597

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.